Please login to the form below

Not currently logged in
Email:
Password:

antidepressant

This page shows the latest antidepressant news and features for those working in and with pharma, biotech and healthcare.

Sage surges after depression drug gets rapid path to approval

Sage surges after depression drug gets rapid path to approval

That’s been an option for cancer drugs for a while, but this is thought to be the first time a truncated pathway has been used for an antidepressant. ... In contrast, current antidepressants can take weeks or months to start working and often come with

Latest news

  • Daily Brief Daily Brief

    Two Phase III clinical studies of its esketamine nasal spray in patients with treatment-resistant depression, combined with a newly initiated oral antidepressant, produced a clinically meaningful rapid reduction of depressive

  • Alkermes slumps as FDA turns down depression drug Alkermes slumps as FDA turns down depression drug

    Alkermes has been hit hard by the FDA’s rejection of antidepressant candidate ALKS 5461 - citing a lack of evidence that it was clinically effective. ... Despite the large number of approved agents, the majority of MDD patients treated with standard

  • Concordia accused of overcharging NHS for thyroid drug Concordia accused of overcharging NHS for thyroid drug

    ruling. Meanwhile, earlier in 2016 the CMA fined number of pharmaceutical companies in relation to ‘pay-for-delay’deals that affected the supply of generic paroxetine, an antidepressant developed by GlaxoSmithKline.

  • Lilly mulls divestment of its animal health operations Lilly mulls divestment of its animal health operations

    Alimta (pemetrexed) and antidepressant Cymbalta (duloxetine) resulting from generic competition.

  • Lundbeck and Otsuka start phase III for Rexulti in bipolar Lundbeck and Otsuka start phase III for Rexulti in bipolar

    Rexulti is one of a string of new drugs at Lundbeck - along with Abilify and antidepressant Brintellix (vortioxetine) - which it is banking on to help it weather the loss of patent ... protection for Abilify and former blockbuster antidepressant

More from news
Approximately 9 fully matching, plus 249 partially matching documents found.

Latest Intelligence

  • Pharma deals during June 2014 Pharma deals during June 2014

    Pfizer is not the only major pharma in this position; also this month GSK settled US claims of irregular marketing activities in asthma and antidepressants at a reported $105m.

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    This was especially true in the “ landmark” case of Pfizer's antidepressant reboxetine, with IQWiG spending two years obtaining all the data it needed from Pfizer. “

  • Interview: Michel Goldman, Innovative Medicines Initiative Interview: Michel Goldman, Innovative Medicines Initiative

    antidepressants. "Another project, by the IMIDIA consortium on diabetes, has generated cell lines which reproduce the response of insulin-secreting cells in the pancreas, the beta cells, and these beta cell

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics